Tara Graff, DO
Medical Oncology · Clive, IANPI 1356584080
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AstraZeneca at 25.8% of the total. Among medical oncology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $1179.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$181K
- AbbVie$91K
- Genmab U.S., Inc.$85K
- Beigene USA, Inc.$80K
- Genentech USA, Inc.$37K
- Lilly USA, LLC$33K
- plus $194K from 22 others
Across 224 payments — averaging $12,431 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$908K
- AbbVie$639K
- Janssen Research & Development, LLC$290K
- Genentech, Inc.$229K
- Merck$169K
- Beone Medicines Ltd.$128K
- plus $422K from 11 others
What the payments were for
- Consulting fees$346,14349%
- Speaking & faculty fees$304,10943%
- Travel & lodging$35,5095%
- Food & beverage$15,8912%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 130 | $181,276 |
| AbbVie(2 entities) | 95 | $90,829 |
| Genmab U.S., Inc. | 88 | $84,789 |
| Beigene USA, Inc. | 57 | $79,664 |
| Genentech USA, Inc. | 38 | $37,435 |
| Lilly USA, LLC | 17 | $33,383 |
| Gilead(2 entities) | 12 | $31,464 |
| Bristol Myers Squibb | 33 | $31,228 |
| Adaptive Biotechnologies Corporation | 32 | $23,099 |
| Incyte Corporation | 10 | $14,510 |
| E.r. Squibb & Sons, L.L.C. | 12 | $13,440 |
| ADC Therapeutics America, Inc. | 13 | $13,236 |
| Janssen Research & Development, LLC | 2 | $12,600 |
| Morphosys, US Inc. | 6 | $11,085 |
| Astrazeneca UK Limited | 8 | $10,573 |
| Beone Medicines USA, Inc. | 10 | $10,162 |
| Eli Lilly | 3 | $5,759 |
| TG Therapeutics, Inc. | 8 | $4,241 |
| Genentech, Inc. | 4 | $3,785 |
| Pfizer | 4 | $3,073 |
| Karyopharm Therapeutics Inc. | 2 | $2,760 |
| Kyowa Kirin, Inc. | 1 | $2,400 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $306 |
| Blueprint Medicines Corporation | 2 | $257 |
| Caris MPI, Inc. | 2 | $248 |
| Sanofi | 1 | $50 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$701,685 in reported general payments places this provider in the 95th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 138 | $1,951,348 |
| Lenalidomide | 79 | $989,209 |
| BrukinsaZanubrutinib | 42 | $593,410 |
| RevlimidLenalidomide | 26 | $541,247 |
| ImbruvicaIbrutinib | 33 | $486,240 |
| KisqaliRibociclib Succinate | 11 | $155,900 |
| Abiraterone Acetate | 13 | $56,535 |
| EliquisApixaban | 70 | $50,801 |
| XareltoRivaroxaban | 30 | $19,267 |
| Exemestane | 17 | $4,999 |
| Anastrozole | 301 | $4,240 |
| Letrozole | 210 | $4,132 |
| Acyclovir | 320 | $3,489 |
| Tamoxifen Citrate | 75 | $2,319 |
| Dexamethasone | 84 | $1,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $181,276 | $1,951,348138 claims |
| Beigene USA, Inc.Brukinsa | $79,664 | $593,41042 claims |
| Bristol Myers SquibbRevlimid | $31,228 | $541,24726 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $306 | $486,24033 claims |
| PfizerEliquis | $3,073 | $50,80170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 47 medical oncology providers in Iowa.
Other medical oncology in Clive
- Roscoe MortonClive$3K
- Amy HughesClive$879
- Jun ZhangIowa City$377K
- Mathew WehbeDes Moines$120K
- Ann StrohCedar Rapids$65K
- Praveen VikasFairfield$30K
- Giselle MeryDes Moines$12K
- John RiethIowa City$11K
- Mark BurkardIowa City$10K
- Emily BrugioniDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.